Roles	0	5	O
of	6	8	O
cell	9	13	O
adhesion	14	22	O
molecules	23	32	O
in	33	35	O
tumor	36	41	B-Pathological_formation
angiogenesis	42	54	O
induced	55	62	O
by	63	65	O
cotransplantation	66	83	O
of	84	86	O
cancer	87	93	B-Cell
and	94	97	O
endothelial	98	109	B-Cell
cells	110	115	I-Cell
to	116	118	O
nude	119	123	B-Organism
rats	124	128	I-Organism
.	128	129	O

Roles	131	136	O
of	137	139	O
cell	140	144	O
adhesion	145	153	O
molecules	154	163	O
mediating	164	173	O
the	174	177	O
interaction	178	189	O
of	190	192	O
cancer	193	199	B-Cell
and	200	203	O
endothelial	204	215	B-Cell
cells	216	221	I-Cell
in	222	224	O
tumor	225	230	B-Pathological_formation
angiogenesis	231	243	O
were	244	248	O
investigated	249	261	O
using	262	267	O
new	268	271	O
in	272	274	O
vitro	275	280	O
and	281	284	O
in	285	287	O
vivo	288	292	O
model	293	298	O
systems	299	306	O
with	307	311	O
a	312	313	O
cultured	314	322	O
murine	323	329	B-Organism
endothelial	330	341	B-Cell
cell	342	346	I-Cell
line	347	351	I-Cell
(	352	353	O
F	353	354	B-Cell
-	354	355	I-Cell
2	355	356	I-Cell
)	356	357	O
and	358	361	O
human	362	367	B-Organism
cultured	368	376	O
epidermoid	377	387	B-Cell
cancer	388	394	I-Cell
cells	395	400	I-Cell
(	401	402	O
A431	402	406	B-Cell
)	406	407	O
.	407	408	O

The	409	412	O
A431	413	417	B-Cell
cells	418	423	I-Cell
exhibited	424	433	O
typical	434	441	O
in	442	444	O
vitro	445	450	O
cell	451	455	B-Cell
adhesion	456	464	O
to	465	467	O
the	468	471	O
endothelial	472	483	B-Cell
F	484	485	I-Cell
-	485	486	I-Cell
2	486	487	I-Cell
cells	488	493	I-Cell
.	493	494	O

The	495	498	O
initial	499	506	O
step	507	511	O
of	512	514	O
adhesion	515	523	O
was	524	527	O
mediated	528	536	O
by	537	539	O
sialyl	540	546	B-Drug_or_compound
Lewis	547	552	I-Drug_or_compound
(	552	553	I-Drug_or_compound
x	553	554	I-Drug_or_compound
)	554	555	I-Drug_or_compound
(	556	557	O
Le	557	559	B-Drug_or_compound
(	559	560	I-Drug_or_compound
x	560	561	I-Drug_or_compound
)	561	562	I-Drug_or_compound
)	562	563	O
and	564	567	O
sialyl	568	574	B-Drug_or_compound
Le	575	577	I-Drug_or_compound
(	577	578	I-Drug_or_compound
a	578	579	I-Drug_or_compound
)	579	580	I-Drug_or_compound
,	580	581	O
the	582	585	O
carbohydrate	586	598	O
determinants	599	611	O
expressed	612	621	O
on	622	624	O
the	625	628	O
cancer	629	635	B-Cell
cells	636	641	I-Cell
,	641	642	O
and	643	646	O
E	647	648	B-Gene_or_gene_product
-	648	649	I-Gene_or_gene_product
selectin	649	657	I-Gene_or_gene_product
expressed	658	667	O
constitutively	668	682	O
on	683	685	O
F	686	687	B-Cell
-	687	688	I-Cell
2	688	689	I-Cell
cells	690	695	I-Cell
.	695	696	O

Prolonged	697	706	O
culture	707	714	O
led	715	718	O
to	719	721	O
the	722	725	O
implantation	726	738	O
of	739	741	O
cancer	742	748	B-Cell
cells	749	754	I-Cell
into	755	759	O
the	760	763	O
monolayer	764	773	O
of	774	776	O
the	777	780	O
F	781	782	B-Cell
-	782	783	I-Cell
2	783	784	I-Cell
cells	785	790	I-Cell
,	790	791	O
which	792	797	O
was	798	801	O
mediated	802	810	O
mainly	811	817	O
by	818	820	O
alpha	821	826	B-Gene_or_gene_product
(	826	827	I-Gene_or_gene_product
3	827	828	I-Gene_or_gene_product
)	828	829	I-Gene_or_gene_product
beta	829	833	I-Gene_or_gene_product
(	833	834	I-Gene_or_gene_product
1	834	835	I-Gene_or_gene_product
)	835	836	I-Gene_or_gene_product
-	836	837	I-Gene_or_gene_product
integrin	837	845	I-Gene_or_gene_product
.	845	846	O

F	847	848	B-Cell
-	848	849	I-Cell
2	849	850	I-Cell
cells	851	856	I-Cell
cultured	857	865	O
on	866	868	O
Matrigel	869	877	O
showed	878	884	O
evident	885	892	O
tube	893	897	B-Tissue
formation	898	907	O
,	907	908	O
and	909	912	O
coculture	913	922	O
of	923	925	O
F	926	927	B-Cell
-	927	928	I-Cell
2	928	929	I-Cell
cells	930	935	I-Cell
with	936	940	O
A431	941	945	B-Cell
cells	946	951	I-Cell
led	952	955	O
to	956	958	O
the	959	962	O
formation	963	972	O
of	973	975	O
A431	976	980	B-Cell
cell	981	985	I-Cell
nests	986	991	O
constantly	992	1002	O
surrounded	1003	1013	O
by	1014	1016	O
tube	1017	1021	O
-	1021	1022	O
like	1022	1026	O
networks	1027	1035	O
consisting	1036	1046	O
of	1047	1049	O
F	1050	1051	B-Cell
-	1051	1052	I-Cell
2	1052	1053	I-Cell
cells	1054	1059	I-Cell
.	1059	1060	O

This	1061	1065	O
in	1066	1068	O
vitro	1069	1074	O
morphogenesis	1075	1088	O
was	1089	1092	O
inhibited	1093	1102	O
by	1103	1105	O
the	1106	1109	O
addition	1110	1118	O
of	1119	1121	O
anti	1122	1126	O
-	1126	1127	O
sialyl	1127	1133	B-Drug_or_compound
Le	1134	1136	I-Drug_or_compound
(	1136	1137	I-Drug_or_compound
x	1137	1138	I-Drug_or_compound
)	1138	1139	I-Drug_or_compound
/	1139	1140	O
Le	1140	1142	B-Drug_or_compound
(	1142	1143	I-Drug_or_compound
a	1143	1144	I-Drug_or_compound
)	1144	1145	I-Drug_or_compound
or	1146	1148	O
anti	1149	1153	O
-	1153	1154	O
beta	1154	1158	B-Gene_or_gene_product
(	1158	1159	I-Gene_or_gene_product
1	1159	1160	I-Gene_or_gene_product
)	1160	1161	I-Gene_or_gene_product
-	1161	1162	I-Gene_or_gene_product
integrin	1162	1170	I-Gene_or_gene_product
antibodies	1171	1181	O
,	1181	1182	O
which	1183	1188	O
led	1189	1192	O
to	1193	1195	O
the	1196	1199	O
formation	1200	1209	O
of	1210	1212	O
cancer	1213	1219	B-Cell
cell	1220	1224	I-Cell
aggregates	1225	1235	O
that	1236	1240	O
were	1241	1245	O
independent	1246	1257	O
from	1258	1262	O
the	1263	1266	O
F	1267	1268	B-Cell
-	1268	1269	I-Cell
2	1269	1270	I-Cell
cell	1271	1275	I-Cell
networks	1276	1284	O
.	1284	1285	O

This	1286	1290	O
in	1291	1293	O
vitro	1294	1299	O
morphological	1300	1313	O
appearance	1314	1324	O
was	1325	1328	O
exactly	1329	1336	O
reproduced	1337	1347	O
in	1348	1350	O
the	1351	1354	O
in	1355	1357	O
vivo	1358	1362	O
tumors	1363	1369	B-Pathological_formation
,	1369	1370	O
which	1371	1376	O
were	1377	1381	O
formed	1382	1388	O
when	1389	1393	O
the	1394	1397	O
mixture	1398	1405	O
of	1406	1408	O
A431	1409	1413	B-Cell
and	1414	1417	O
F	1418	1419	B-Cell
-	1419	1420	I-Cell
2	1420	1421	I-Cell
cells	1422	1427	I-Cell
at	1428	1430	O
the	1431	1434	O
ratio	1435	1440	O
of	1441	1443	O
10	1444	1446	O
:	1446	1447	O
1	1447	1448	O
were	1449	1453	O
cotransplanted	1454	1468	O
s	1469	1470	O
.	1470	1471	O
c	1471	1472	O
.	1472	1473	O
into	1474	1478	O
the	1479	1482	O
back	1483	1487	B-Organism_subdivision
of	1488	1490	O
nude	1491	1495	B-Organism
rats	1496	1500	I-Organism
.	1500	1501	O

The	1502	1505	O
tumors	1506	1512	B-Pathological_formation
of	1513	1515	O
A431	1516	1520	B-Cell
supplemented	1521	1533	O
with	1534	1538	O
F	1539	1540	B-Cell
-	1540	1541	I-Cell
2	1541	1542	I-Cell
cells	1543	1548	I-Cell
were	1549	1553	O
profoundly	1554	1564	O
vascularized	1565	1577	O
throughout	1578	1588	O
by	1589	1591	O
the	1592	1595	O
tubular	1596	1603	B-Tissue
structures	1604	1614	I-Tissue
formed	1615	1621	O
by	1622	1624	O
F	1625	1626	B-Cell
-	1626	1627	I-Cell
2	1627	1628	I-Cell
cells	1629	1634	I-Cell
,	1634	1635	O
the	1636	1639	O
lumen	1640	1645	B-Immaterial_anatomical_entity
of	1646	1648	O
which	1649	1654	O
contained	1655	1664	O
the	1665	1668	O
host	1669	1673	O
rat	1674	1677	B-Organism
blood	1678	1683	B-Cell
cells	1684	1689	I-Cell
.	1689	1690	O

The	1691	1694	O
tumor	1695	1700	B-Pathological_formation
mass	1701	1705	O
thus	1706	1710	O
formed	1711	1717	O
was	1718	1721	O
an	1722	1724	O
average	1725	1732	O
5	1733	1734	O
.	1734	1735	O
8	1735	1736	O
-	1736	1737	O
fold	1737	1741	O
as	1742	1744	O
large	1745	1750	O
as	1751	1753	O
control	1754	1761	O
A431	1762	1766	B-Pathological_formation
tumors	1767	1773	I-Pathological_formation
that	1774	1778	O
were	1779	1783	O
grown	1784	1789	O
without	1790	1797	O
F	1798	1799	B-Cell
-	1799	1800	I-Cell
2	1800	1801	I-Cell
cells	1802	1807	I-Cell
.	1807	1808	O

The	1809	1812	O
co	1813	1815	O
-	1815	1816	O
injection	1816	1825	O
of	1826	1828	O
anti	1829	1833	O
-	1833	1834	O
Le	1834	1836	B-Drug_or_compound
(	1836	1837	I-Drug_or_compound
x	1837	1838	I-Drug_or_compound
)	1838	1839	I-Drug_or_compound
/	1839	1840	O
Le	1840	1842	B-Drug_or_compound
(	1842	1843	I-Drug_or_compound
a	1843	1844	I-Drug_or_compound
)	1844	1845	I-Drug_or_compound
or	1846	1848	O
anti	1849	1853	O
-	1853	1854	O
beta	1854	1858	B-Gene_or_gene_product
(	1858	1859	I-Gene_or_gene_product
1	1859	1860	I-Gene_or_gene_product
)	1860	1861	I-Gene_or_gene_product
-	1861	1862	I-Gene_or_gene_product
integrin	1862	1870	I-Gene_or_gene_product
antibodies	1871	1881	O
produced	1882	1890	O
a	1891	1892	O
marked	1893	1899	O
reduction	1900	1909	O
in	1910	1912	O
the	1913	1916	O
size	1917	1921	O
of	1922	1924	O
A431	1925	1929	B-Pathological_formation
tumors	1930	1936	I-Pathological_formation
,	1936	1937	O
which	1938	1943	O
were	1944	1948	O
not	1949	1952	O
vascularized	1953	1965	O
and	1966	1969	O
accompanied	1970	1981	O
an	1982	1984	O
independent	1985	1996	O
tiny	1997	2001	O
remnant	2002	2009	O
clump	2010	2015	O
of	2016	2018	O
F	2019	2020	B-Cell
-	2020	2021	I-Cell
2	2021	2022	I-Cell
cells	2023	2028	I-Cell
.	2028	2029	O

The	2030	2033	O
size	2034	2038	O
of	2039	2041	O
these	2042	2047	O
A431	2048	2052	B-Pathological_formation
tumors	2053	2059	I-Pathological_formation
did	2060	2063	O
not	2064	2067	O
differ	2068	2074	O
significantly	2075	2088	O
from	2089	2093	O
those	2094	2099	O
of	2100	2102	O
control	2103	2110	O
A431	2111	2115	B-Pathological_formation
tumors	2116	2122	I-Pathological_formation
raised	2123	2129	O
without	2130	2137	O
F	2138	2139	B-Cell
-	2139	2140	I-Cell
2	2140	2141	I-Cell
cells	2142	2147	I-Cell
.	2147	2148	O

These	2149	2154	O
results	2155	2162	O
indicate	2163	2171	O
that	2172	2176	O
the	2177	2180	O
interaction	2181	2192	O
of	2193	2195	O
tumor	2196	2201	B-Cell
cells	2202	2207	I-Cell
and	2208	2211	O
endothelial	2212	2223	B-Cell
cells	2224	2229	I-Cell
in	2230	2232	O
orderly	2233	2240	O
tumor	2241	2246	B-Pathological_formation
angiomorphogenesis	2247	2265	O
is	2266	2268	O
highly	2269	2275	O
dependent	2276	2285	O
on	2286	2288	O
the	2289	2292	O
action	2293	2299	O
of	2300	2302	O
cell	2303	2307	O
adhesion	2308	2316	O
molecules	2317	2326	O
mediating	2327	2336	O
the	2337	2340	O
adhesion	2341	2349	O
of	2350	2352	O
cancer	2353	2359	B-Cell
cells	2360	2365	I-Cell
to	2366	2368	O
endothelial	2369	2380	B-Cell
cells	2381	2386	I-Cell
,	2386	2387	O
inhibition	2388	2398	O
of	2399	2401	O
which	2402	2407	O
remarkably	2408	2418	O
retards	2419	2426	O
tumor	2427	2432	B-Pathological_formation
growth	2433	2439	O
and	2440	2443	O
angiogenesis	2444	2456	O
.	2456	2457	O

